4 results
Approved WMOCompleted
To determine the safety and efficacy of Dimebon in patients with mild-to-moderate Huntington Disease
Approved WMOCompleted
To determine the safety and efficacy of Dimebon in patients with mild to moderate Huntington Disease
Approved WMOCompleted
To evaluate the long-term safety and tolerability of Dimebon in AD patients who have successfully completed 26 weeks of blinded treatment in the CONNECTION Study (DIM14) (hereafter referred to as *CONNECTION*).
Approved WMOCompleted
The study aims to limit the use of anthracyclines and to reduce the dose of ATRA. Another aim is to stratify treatment by risk group: standard risk - WBC <10 x 109/l : high risk - WBC >=10 x 109/l. Furthermore this study aims to…